Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-04-02 9:25 pm Purchase |
2025-03-31 | 13D | Pyxis Oncology, Inc. PYXS |
Lara Sullivan, M.D. | 7,543,007 11.210% |
918,308 (+13.86%) |
Filing History |
| 2025-02-14 4:01 pm Sale |
2024-12-31 | 13G | Pyxis Oncology, Inc. PYXS |
Ridgeback Capital Investments L.P. | 359,231 0.600% |
-3,985,997 (-91.73%) |
Filing History |
| 2025-02-14 08:48 am Sale |
2024-12-31 | 13G | Pyxis Oncology, Inc. PYXS |
Deep Track Capital, LP | 0 0.000% |
-4,184,100 (Position Closed) |
Filing History |
| 2025-02-04 3:45 pm Purchase |
2024-12-31 | 13G | Pyxis Oncology, Inc. PYXS |
BLACKROCK INC BLK |
3,344,141 5.600% |
3,344,141 (New Position) |
Filing History |
| 2024-12-23 6:31 pm Purchase |
2024-12-23 | 13D | Pyxis Oncology, Inc. PYXS |
Lara Sullivan, M.D. | 6,624,699 10.300% |
1,135,000 (+20.68%) |
Filing History |
| 2024-12-16 4:04 pm Purchase |
2024-12-09 | 13G | Pyxis Oncology, Inc. PYXS |
Integrated Core Strategies (US) LLC | 3,160,139 5.300% |
3,160,139 (New Position) |
Filing History |
| 2024-11-12 11:53 am Purchase |
2024-09-30 | 13G | Pyxis Oncology, Inc. PYXS |
Laurion Capital Management LP | 3,625,974 6.150% |
455,171 (+14.36%) |
Filing History |
| 2024-11-06 4:36 pm Unchanged |
2024-09-30 | 13G | Pyxis Oncology, Inc. PYXS |
Bayer World Investments B.V. | 2,742,338 4.700% |
0 (Unchanged) |
Filing History |
| 2024-04-03 5:10 pm Purchase |
2024-03-26 | 13D | Pyxis Oncology, Inc. PYXS |
Lara Sullivan, M.D. | 5,489,699 8.890% |
1,319,425 (+31.64%) |
Filing History |
| 2024-03-08 4:03 pm Purchase |
2024-02-27 | 13G | Pyxis Oncology, Inc. PYXS |
Deep Track Capital, LP | 4,184,100 7.870% |
4,184,100 (New Position) |
Filing History |
| 2024-02-14 4:00 pm Sale |
2023-12-31 | 13G | Pyxis Oncology, Inc. PYXS |
TANG CAPITAL PARTNERS LP | 0 0.000% |
-3,470,700 (Position Closed) |
Filing History |
| 2024-02-14 09:28 am Sale |
2023-12-31 | 13G | Pyxis Oncology, Inc. PYXS |
BIOTECHNOLOGY VALUE FUND L P | 0 0.000% |
-2,938,851 (Position Closed) |
Filing History |
| 2024-01-26 4:36 pm Purchase |
2024-01-26 | 13G | Pyxis Oncology, Inc. PYXS |
Ridgeback Capital Investments L.P. | 4,345,228 9.800% |
4,345,228 (New Position) |
Filing History |
| 2023-04-04 4:58 pm Purchase |
2023-03-24 | 13D | Pyxis Oncology, Inc. PYXS |
Lara Sullivan, M.D. | 4,170,274 10.200% |
703,379 (+20.29%) |
Filing History |
| 2023-03-23 4:20 pm Purchase |
2023-03-17 | 13G | Pyxis Oncology, Inc. PYXS |
PFIZER INC PFE |
7,032,770 19.020% |
1,811,594 (+34.70%) |
Filing History |
| 2023-02-14 4:45 pm Sale |
2022-12-31 | 13G | Pyxis Oncology, Inc. PYXS |
RA Capital Management, L.P. | 0 0.000% |
-2,282,173 (Position Closed) |
Filing History |
| 2023-02-14 4:00 pm Purchase |
2022-12-31 | 13G | Pyxis Oncology, Inc. PYXS |
TANG CAPITAL PARTNERS LP | 3,470,700 9.900% |
1,489,274 (+75.16%) |
Filing History |
| 2023-02-14 10:00 am Sale |
2022-12-31 | 13G | Pyxis Oncology, Inc. PYXS |
RTW Investments, LP | 0 0.000% |
-2,120,760 (Position Closed) |
Filing History |
| 2023-02-13 6:13 pm Purchase |
2022-12-31 | 13G | Pyxis Oncology, Inc. PYXS |
BIOTECHNOLOGY VALUE FUND L P | 2,938,851 8.400% |
1,147,500 (+64.06%) |
Filing History |
| 2023-02-13 5:14 pm Purchase |
2022-12-31 | 13G | Pyxis Oncology, Inc. PYXS |
PFIZER INC PFE |
5,221,176 14.880% |
2,229,654 (+74.53%) |
Filing History |